FDA MAP
  • Home
  • Training
    • WORKSHOPS
    • WEBINARS
    • CUSTOM TRAINING
  • SERVICES
    • REGULATORY SERVICES
    • FDA AUDITING
    • QUALITY ASSURANCE
    • CLINICAL TRIAL SERVICES
  • News Releases
  • About Us
Webinars>>​Off-Label Promotion                                                                   Sydney Time
FDA Permitted Off-Label Promotion: The Changing Regulatory Paradigm 

FDA has publicly acknowledged that many regulated products have uses beyond what they have been approved for. FDA also recognizes that these unapproved uses may be beneficial to some patients. The so-called off-label uses may be well-known to the physicians and manufacturers. While there are no restrictions on a physician prescribing off-label uses of a product, manufacturers are prohibited for “actively” promoting an off-label use. Recent legal developments have challenged the age-old FDA practice of restricting all discussion of off-label use of a given product by its manufacturer. In light of these, several strategies have evolved to legally discuss off-label uses of FDA-approved products. FDA’s recent rules under which manufacturers can educate physicians and, indirectly, even patients about new uses of their products, have changed the regulatory paradigm. This seminar will discuss the regulatory perspective on promoting off-label uses for manufacturers.
Why should you attend:

Recently the US courts have made some high-profile decisions regarding FDA’s punitive actions to manufacturers accused of off-label promotion. One case, the Caronia case, has been in much discussion since in that case the court sided with the defendant accused of off-label promotion leading to speculation of its impact on FDA’s enforcement of its rules regarding off-label promotion. The legal discussion apart, these cases have raised new regulatory questions about FDA-acceptable practices for promoting off-label uses for approved products. This seminar will discuss the regulatory impact of recent court decisions and strategies for introducing new uses for approved products.
Topics Covered in the Session:
  • Current FDA accepted definition of off-label, in-label, published and anecdotal information
  • FDA guidance documents about off-label promotion
  • Review of case-studies from unsuccessful and successful promotion of off-label uses
  • Practical tips for training of sales and marketing teams in off-label uses of products
  • Regulatory strategies for converting off-label uses to in-label uses
Who will benefit:

This webinar will provide valuable information to:
  • Manufacturers of FDA regulated products: Drug, Medical Device and Biotech Companies, Dietary Supplement manufacturers
  • Marketing and advertising professionals
  • Financial analysts and investors, venture capitalists, insurance professionals
  • Legal experts involved in advising manufacturers of marketed products
  • Senior management for companies developing new products for US market
  • Regulatory affairs professionals, research analysts
Date: December 12, 2016
Duration:
60 Minutes
Time: 1 PM AEST
Register Online

Speaker
Mukesh Kumar, PhD, RAC, VP (Regulatory Affairs and Quality Assurance), Amarex Clinical Research, USA
​

Picture

    For more info, fill the box below. We will contact you within 24 hrs.

Submit
For additional information on the workshop agenda and logistics, please call 410-501-5777 or email: info@fdamap.com

Our Services

  • Workshops
  • Webinars
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions
  • Corporate Registration
  • Certification Program
  • Smart Recruitment
  • Corporate Registration - Online Workshop​

Company

  • About Us​
  • Testimonials
  • Free Resources
  • Newsletter
  • Videos (Free Tutorials)

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy
  • News Archive
Consultation Service
FDA Training Company
Copyright © 2022 FDAMap.com
Use of this Web site constitutes acceptance of the FDAMap Terms of Use and Privacy Policy.